Dr. Reddy's Laboratories

RDY · NYSE · India

Share price · RDY

$14.98+2.83 (+23.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.8M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RDY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Jul 2026-9.4%
  2. 29 Jun 2026-3.4%
  3. 14 May 2026+3.8%
  4. 12 May 2026-5.2%
  5. 23 Apr 2026+5.8%
  6. 1 Apr 2026-2.7%

Share of unusual movement by asset

For each asset, the share of RDY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Olutasidenib
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—54%
Sessions with no dated event—46%

Assets

(4 total)
4Total Assets
2Approved
2Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
COX-2Small molecule
Migraine
Approved
Mutant IDH1Small molecule
Acute Myeloid LeukemiaGlioma
Relapsed/Refractory Acute Myeloid Leukemia
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
Phase 3
EGFR/HER1, HER2, HER4Small molecule
Non-Small Cell Lung CancerBreast Cancer
HER2-Positive Breast Cancer

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
PyrotinibPhase 1/2HER2-expressing Advanced Solid Tumors
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (1)
PyrotinibPhase 1/2Advanced Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
2027 (2)
June 2027 (1)
PyrotinibPhase 3Breast Cancer
Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗
What to watch
July 2027 (1)
HLX15Phase 3Newly Diagnosed Multiple Myeloma
Est. primary completion 2027-07 · NCT06895512 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
OlutasidenibPhase 2High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma …
Est. primary completion 2029-06 · NCT06161974 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
OlutasidenibPhase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
Est. primary completion 2030-09 · NCT07604064 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.8B$323M$172M—$548M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.4B$276M$85M—$548M operating cash flowreport ↗
2023-FY$3.0B$240M$70M—$730M operating cash flowreport ↗
2022-FY$2.9B$235M$196M—$377M operating cash flowreport ↗
2021-FY$2.6B$223M$202M—$482M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

No Form 4 transactions on file in the stored window.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 245 reporting institutions held 120.4M shares ($1.6B, 14.4% of shares outstanding).

#InstitutionSharesValue
1Robeco Institutional Asset Management B.V.17,177,882$237.9M
2BlackRock, Inc.11,587,127$160.5M
3ROYAL BANK OF CANADA9,984,082$138.3M
4MORGAN STANLEY9,371,594$129.8M
5Aikya Investment Management Ltd7,999,796$110.8M
6RENAISSANCE TECHNOLOGIES LLC7,859,728$108.9M
7DIMENSIONAL FUND ADVISORS LP5,323,248$73.7M
8JPMORGAN CHASE & CO4,371,378$58.8M
9STATE STREET CORP4,026,207$55.8M
10BNP PARIBAS FINANCIAL MARKETS3,183,971$44.1M
11VANGUARD CAPITAL MANAGEMENT LLC3,100,911$42.9M
12FRANKLIN RESOURCES INC2,856,094$39.6M
13MARSHALL WACE, LLP2,664,306$36.9M
14ALLIANCEBERNSTEIN L.P.2,541,889$35.7M
15VANGUARD PORTFOLIO MANAGEMENT LLC1,773,738$24.6M